Long Non-Coding RNAs: Crucial Regulators in Alzheimer's Disease Pathogenesis and Prospects for Precision Medicine
- PMID: 39907902
- DOI: 10.1007/s12035-025-04729-4
Long Non-Coding RNAs: Crucial Regulators in Alzheimer's Disease Pathogenesis and Prospects for Precision Medicine
Abstract
Long non-coding RNAs (LncRNAs) have emerged as pivotal regulators in the pathogenesis of Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. With the capacity to modulate gene expression at various levels, LncRNAs are implicated in multiple pathological mechanisms of AD, including amyloid-beta (Aβ) accumulation, tau protein phosphorylation, neuroinflammation, and neuronal apoptosis. Recent studies have highlighted the potential of LncRNAs as diagnostic biomarkers and therapeutic targets due to their differential expression patterns in AD patients. This review synthesizes current knowledge on the role of LncRNAs in AD, focusing on their involvement in key molecular pathways and their promise as indicators for early diagnosis and prognosis. We discuss the regulatory networks of LncRNAs in the context of AD, their interaction with miRNAs, and the implications for developing novel therapeutic strategies. Despite the complexity and variability in LncRNA function, the prospect of harnessing these molecules for precision medicine in AD is gaining momentum. The translational potential of LncRNA-based interventions offers a new frontier in the quest for effective treatments and a deeper understanding of the molecular underpinnings of AD.
Keywords: Alzheimer’s disease; Liquid biopsy; Long non-coding RNA; Molecular mechanism.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing interests.
Similar articles
-
Non-coding RNAs in the pathogenesis of Alzheimer's disease: β-amyloid aggregation, Tau phosphorylation and neuroinflammation.Mol Biol Rep. 2025 Jan 31;52(1):183. doi: 10.1007/s11033-025-10284-x. Mol Biol Rep. 2025. PMID: 39890684 Review.
-
Emerging roles of long non-coding RNAs in the pathogenesis of Alzheimer's disease.Ageing Res Rev. 2019 Mar;50:19-26. doi: 10.1016/j.arr.2019.01.001. Epub 2019 Jan 2. Ageing Res Rev. 2019. PMID: 30610928 Review.
-
Harnessing the potential of long non-coding RNAs in the pathophysiology of Alzheimer's disease.Exp Neurol. 2025 Mar;385:115134. doi: 10.1016/j.expneurol.2024.115134. Epub 2024 Dec 29. Exp Neurol. 2025. PMID: 39740737 Review.
-
Insights into lncRNAs in Alzheimer's disease mechanisms.RNA Biol. 2021 Jul;18(7):1037-1047. doi: 10.1080/15476286.2020.1788848. Epub 2020 Jul 14. RNA Biol. 2021. PMID: 32605500 Free PMC article. Review.
-
Exploring the Therapeutic Potential of Noncoding RNAs in Alzheimer's Disease.Protein Pept Lett. 2024;31(11):862-883. doi: 10.2174/0109298665335550241011080252. Protein Pept Lett. 2024. PMID: 39558496 Review.
Cited by
-
Cannabinerol Restores mRNA Splicing Defects Induced by β-Amyloid in an In Vitro Model of Alzheimer's Disease: A Transcriptomic Study.Int J Mol Sci. 2025 Mar 28;26(7):3113. doi: 10.3390/ijms26073113. Int J Mol Sci. 2025. PMID: 40243843 Free PMC article.
-
Lead Induces Mitochondrial Dysregulation in SH-SY5Y Neuroblastoma Cells via a lncRNA/circRNA-miRNA-mRNA Interdependent Networks.Int J Mol Sci. 2025 Jul 17;26(14):6851. doi: 10.3390/ijms26146851. Int J Mol Sci. 2025. PMID: 40725099 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical